Cargando…
Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data
BACKGROUND: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled trials (RCT) of new treatments for relapsing remitting multiple sclerosis (RRMS) have decreased substantially during the last two decades. The causes of these changes are not clear. We consider a bette...
Autores principales: | Stellmann, Jan-Patrick, Neuhaus, Anneke, Herich, Lena, Schippling, Sven, Roeckel, Matthias, Daumer, Martin, Martin, Roland, Heesen, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510222/ https://www.ncbi.nlm.nih.gov/pubmed/23209717 http://dx.doi.org/10.1371/journal.pone.0050347 |
Ejemplares similares
-
Validating Predictors of Disease Progression in a Large Cohort of Primary-Progressive Multiple Sclerosis Based on a Systematic Literature Review
por: Stellmann, Jan-Patrick, et al.
Publicado: (2014) -
Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting
por: von Gumberz, Johanna, et al.
Publicado: (2016) -
Prognostic Risk Estimates of Patients with Multiple Sclerosis and Their Physicians: Comparison to an Online Analytical Risk Counseling Tool
por: Heesen, Christoph, et al.
Publicado: (2013) -
Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?
por: Stellmann, Jan-Patrick, et al.
Publicado: (2015) -
Ecological Validity of Walking Capacity Tests in Multiple Sclerosis
por: Stellmann, J. P., et al.
Publicado: (2015)